We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

2,364 hedge funds and large institutions have $81.1B invested in Bristol-Myers Squibb in 2023 Q4 according to their latest regulatory filings, with 253 funds opening new positions, 672 increasing their positions, 1,209 reducing their positions, and 240 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more call options, than puts

Call options by funds: $1.7B | Put options by funds: $1.2B

2.47% more ownership

Funds ownership: 75.18%77.65% (+2.5%)

5% more first-time investments, than exits

New positions opened: 253 | Existing positions closed: 240

1% less funds holding

Funds holding: 2,3882,364 (-24)

11% less capital invested

Capital invested by funds: $91.2B → $81.1B (-$10.2B)

43% less funds holding in top 10

Funds holding in top 10: 4224 (-18)

44% less repeat investments, than reductions

Existing positions increased: 672 | Existing positions reduced: 1,209

Holders
2,364
Holders Change
-24
Holders Change %
-1.01%
% of All Funds
34.46%
Holding in Top 10
24
Holding in Top 10 Change
-18
Holding in Top 10 Change %
-42.86%
% of All Funds
0.35%
New
253
Increased
672
Reduced
1,209
Closed
240
Calls
$1.7B
Puts
$1.2B
Net Calls
+$498M
Net Calls Change
-$7.96M
Name Holding Trade Value Shares
Change
Change in
Stake
CWM
1351
Compass Wealth Management
Connecticut
$673K -$574K -10,931 -45%
PWP
1352
Private Wealth Partners
California
$673K -$10.3K -197 -1%
RPCONE
1353
Retirement Planning Company of New England
Rhode Island
$672K +$48.4K +922 +8%
MIS
1354
Morningstar Investment Services
Illinois
$671K +$276K +5,251 +67%
USB
1355
Union Savings Bank
Connecticut
$669K +$8.77K +167 +1%
AWA
1356
Arete Wealth Advisors
Illinois
$669K +$22.8K +435 +3%
MBT
1357
Montecito Bank & Trust
California
$663K -$331K -6,308 -33%
AAM
1358
Alphadyne Asset Management
New York
$663K +$164K +3,133 +32%
SPA
1359
Sherbrooke Park Advisers
New York
$662K -$1.37M -26,034 -67%
NPA
1360
Nichols & Pratt Advisers
Massachusetts
$662K
CGL
1361
Clarius Group LLC
Washington
$660K -$173K -3,293 -20%
AF
1362
Apexium Financial
Texas
$659K +$254K +4,842 +61%
CS
1363
Cannell & Spears
New York
$658K -$18.1K -344 -3%
BFM
1364
Boston Financial Management
Massachusetts
$656K -$22.1K -421 -3%
PIMG
1365
Patriot Investment Management Group
Tennessee
$655K -$20.1K -382 -3%
BONH
1366
Bank of New Hampshire
New Hampshire
$654K -$578K -11,015 -46%
CAI
1367
Capital Advisors Inc
Oklahoma
$654K -$7.61K -145 -1%
BIM
1368
Bridges Investment Management
Nebraska
$653K
DS
1369
DRW Securities
Illinois
$653K +$459K +8,740 +219%
HT
1370
Headlands Technologies
Illinois
$650K +$664K +12,659 New
RWMG
1371
Redwood Wealth Management Group
New Jersey
$648K +$118K +2,247 +22%
SMH
1372
Sanders Morris Harris
Texas
$645K -$3.03M -57,657 -82%
CB
1373
Centennial Bank
Arkansas
$643K +$1.16K +22 +0.2%
VH
1374
Visionary Horizons
Tennessee
$643K +$657K +12,522 New
GI
1375
GAMMA Investing
California
$639K +$686K +13,076 New

BMY Hedge Fund Activity: Q4 2023 in Review

2,364 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q4 2023, worth a combined $81.1B — down 11% from $91.2B a quarter earlier.

Buyers outnumbered sellers: 253 funds opened new BMY positions and 240 closed out — a net gain of 13 holders — while 672 added to existing stakes and 1,209 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.16B. The largest seller was Capital International Investors, cutting an estimated $414M.

  • 2,364 institutional investors held Bristol-Myers Squibb (BMY) as of Q4 2023, down from 2,388 in Q3 2023.
  • Funds reported $81.1B of Bristol-Myers Squibb stock for Q4 2023, down 11% quarter-over-quarter.
  • 253 funds opened new Bristol-Myers Squibb positions in Q4 2023 and 240 closed out, a net change of +13 holders.
  • The largest Bristol-Myers Squibb buyer in Q4 2023 was Morgan Stanley, an estimated $1.16B added.
  • The largest Bristol-Myers Squibb seller in Q4 2023 was Capital International Investors, an estimated $414M sold.

Based on aggregated 13F filings for Q4 2023.